Generic Copaxone Looms; Teva Fights And Prepares For Next Chapter
This article was originally published in The Pink Sheet Daily
Executive Summary
An appeals court ruling on July 26 favoring a faster route to a generic Copaxone brings to the fore longstanding issues of what its regulatory path might look like and how Teva will cope with the erosion of its top product’s sales.